Based in Ann Arbor, Michigan, Zomedica (NYSE American:ZOM) is a veterinary health company offering diagnostic and therapeutic products for companion animals by focusing on the unmet needs of clinical veterinarians.
Similarly Is Zomedica a good investment? In the final analysis, ZOM stock is highly risky and best suited for speculative traders. Yet it’s possible that retail traders will bid the stock up in 2022. And if they abandon Zomedica, it would be a dog-gone shame.
How many employees does Zomedica have? Company Growth (employees)
| Employees (est.) (Dec 2019) | 28 | (+4%) |
|---|---|---|
| Website Visits (Nov 2021) | 26 k | |
| Share Price (Feb 2022) | $0.3 | (-3%) |
| Cybersecurity rating | B | More |
Additionally, Is Truforma FDA approved?
In April 2020, Zomedica announced that they had completed platform verification of TRUFORMA, which confirms the achievement of instrument design specifications, and follows FDA Medical Device design control guidelines to ensure the product was built correctly.
Why did Zomedica stock drop?
The reason behind the decline goes back into the previous week, when Zomedica announced its third-quarter results after the market close on Nov. 12. The veterinary health company reported revenue in the third quarter of only $22,514. It posted a net loss of $6.3 million, or $0.091 per share.
Is Zomedica expected to rise? Zomedica Corp (NYSE American:ZOM)
The 1 analysts offering 12-month price forecasts for Zomedica Corp have a median target of 1.20, with a high estimate of 1.20 and a low estimate of 1.20. The median estimate represents a +292.16% increase from the last price of 0.31.
Will Zomedica recover? ZOM stock will likely struggle to recover in price over the next few months. It’s going to be awhile before this early stage company will again have the chance to prove itself to investors. Having said that, investors with a high appetite for risk, and a willingness to go against the grain, may want to buy today.
Why is Zomedica stock falling? The reason behind the decline goes back into the previous week, when Zomedica announced its third-quarter results after the market close on Nov. 12. The veterinary health company reported revenue in the third quarter of only $22,514. It posted a net loss of $6.3 million, or $0.091 per share.
What is Truforma?
Truforma is a blood testing kit for veterinarians. It’s based on bulk acoustic wave (BAW) sensors from Qorvo (NASDAQ:QRVO). The waves are run through pet blood samples to test for adrenal and thyroid diseases.
What is Zomedica launching? (NYSE American:ZOM) (« Zomedica » or the « Company »), a veterinary health company offering diagnostic and therapeutic products for companion animals, today announced the commercial launch of its newest assay – endogenous ACTH (eACTH) – for the TRUFORMA In-Clinic Biosensor Testing Platform.
What is Truforma Zomedica?
Truforma is a blood testing kit for veterinarians. It’s based on bulk acoustic wave (BAW) sensors from Qorvo (NASDAQ:QRVO). The waves are run through pet blood samples to test for adrenal and thyroid diseases.
When was Zomedica released? In my last article about Zomedica (NYSEAMERICAN:ZOM), I said that the March 30 launch of its Truforma diagnostic platform for dogs and cats couldn’t come soon enough.
Why is Zomedica tanking?
CEO Robert Cohen said the move was precipitated by « changes at our current distributor that we believe have impacted its ability to market our products effectively. » Those words likely startled investors, many of whom decided to sell their shares. Zomedica’s stock price dropped sharply on Thursday.
Will Zomedica go up tomorrow?
Tomorrow’s movement Prediction of Zomedica Pharmaceuticals Corp ZOM as on 08 Apr 2022 appears strongly Bullish . This stock started moving upwards as soon as it opened.
…
Munafa value: 55 as on 08 Fri Apr 2022.
| Upside target | 0.33 |
|---|---|
| Upside target | 0.31 |
| Downside target | 0.3 |
| Downside target | 0.29 |
Will Zomedica stock go up in 2022? Target values for the price of one Zomedica share for May 2022. The weighted average target price per Zomedica share in May 2022 is: 0.36. In May, the positive dynamics for Momo shares will prevail with possible monthly volatility of 11.441% volatility is expected.
Why is Zomedica stock going up? Investors are excited about Zomedica’s sales primarily because of one reason: They’re growing. In the prior-year period, the company didn’t generate any revenue at all. Zomedica barely had any sales during the first three quarters of 2021. The difference-maker was the company’s acquisition of PulseVet last October.
Why is Zomedica stock up?
The big jump came after the veterinary health company provided a sneak peek at its 2021 fourth-quarter and full-year revenue following the market close on Friday. Zomedica reported total revenue in the fourth quarter and full-year 2021 of $4.1 million. The company stated that its gross margin was 73.9%.
Is Castor Maritime a good buy? Castor Maritime Inc.
holds several positive signals and is within a strong rising trend. As the old saying says, « Let the trend be your friend. ‘ ». We therefore consider it to be a good choice at these current levels and we are expecting further gains during the next 3 months.
Does Zomedica have potential?
Estimates are that this market will grow from an estimated valuation of $2.5 billion in 2021 to a projected value of $3.9 billion in 2026.
Is Zomedica a pump and dump? Zomedica Pharmaceuticals (NYSEMKT:ZOM) stock is the latest pump-and-dump looking to take investors for a ride.
